{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:24:25Z","timestamp":1767824665583,"version":"3.49.0"},"reference-count":35,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,7,3]],"date-time":"2009-07-03T00:00:00Z","timestamp":1246579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Anti\u2010tumour necrosis factor (TNF) therapy effectively treats Crohn\u2019s perineal fistulas (CPF); the effect on health\u2010related quality of life (HRQoL) remains unknown.<\/jats:p><jats:p><jats:bold>Aims\u2002<\/jats:bold> To evaluate the effect of anti\u2010TNF therapy on the HRQoL of patients with CPF in daily clinical practice.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Prospective evaluation of clinical and magnetic resonance imaging (MRI) responses, disease activity (Perianal Disease Activity Index \u2013 PDAI), and HRQoL assessment [Inflammatory Bowel Disease Questionnaire (IBDQ)] in patients receiving anti\u2010TNF therapy for CPF treated up to 12\u2003months.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> In all, 26 patients with CPF were treated (mean age 39\u2003years; 19 infliximab, 7 adalimumab). At baseline, 85% patients had impaired IBDQ scores (mean 137; \u2018normal\u2019 &gt;170). At 12\u2003months, mean increases in IBDQ score for infliximab and adalimumab treated patients were 40 and 41 points respectively (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.05). There were significant improvements in all IBDQ subscores (bowel, emotional, systemic, social) at 12\u2003months (all <jats:italic>P\u2003<\/jats:italic>\u2264\u20030.003). Fourteen patients (74%) on infliximab and six on adalimumab (86%) achieved IBDQ score \u2265170. Mean increase in IBDQ score was 50, 34 and 16 points in patients with clinical fistula closure (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.001), clinical response (<jats:italic>P\u2003<\/jats:italic>=\u20030.002) and no response (<jats:italic>n\u2003<\/jats:italic>=\u20031) respectively. IBDQ score increased for patients with MRI healing (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.001) and MRI improvement (<jats:italic>P\u2003<\/jats:italic>=\u20030.016), but not for those with no MRI change (<jats:italic>n\u2003<\/jats:italic>=\u20032). IBDQ correlated significantly with PDAI at baseline and at 12\u2003months.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Anti\u2010TNF therapy improves HRQoL in patients with CPF at 12\u2003months and this improvement is most pronounced in patients with clinical and MRI healing.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2009.04088.x","type":"journal-article","created":{"date-parts":[[2009,7,3]],"date-time":"2009-07-03T13:48:27Z","timestamp":1246628907000},"page":"757-766","source":"Crossref","is-referenced-by-count":49,"title":["Prospective assessment of the effect on quality of life of anti\u2010tumour necrosis factor therapy for perineal Crohn\u2019s fistulas"],"prefix":"10.1111","volume":"30","author":[{"given":"S. C.","family":"NG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"PLAMONDON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"GUPTA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"BURLING","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"KAMM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-10-200111200-00011"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.12.011"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07285.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0016-5085(75)80270-8","article-title":"Clinical patterns in Crohn\u2019s disease: a statistical study of 615 cases","volume":"68","author":"Farmer RG","year":"1975","journal-title":"Gastroenterology"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70420-2"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01561.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01323.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.28.4.378"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.159251"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07674.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02175.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-200709002-00921","article-title":"Impact of Adalimumab (Humira) on patient\u2010reported outcomes among patients with fistulising Crohn\u2019s disease","volume":"102","author":"Colombel JF","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"e_1_2_6_15_2","first-page":"P0777","article-title":"Top\u2010down\u201d anti\u2010tumour necrosis factor therapy for Crohn\u2019s fistulas guided by prospective magnetic resonance imaging to monitor deep tissue healing","author":"Ng SC","year":"2008","journal-title":"Gut"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199501000-00008"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(76)80163-1"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-009-8273-4_2"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92767-1"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90585-1"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-199904001-00003"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(98)80053-6"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800630102"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)05909-9"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(89)90905-0"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200207000-00001"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-007-0395-7"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01268.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.4321\/S1130-01082004000600002"},{"issue":"2","key":"e_1_2_6_30_2","first-page":"S456[#920]","article-title":"Impact of Adalimumab (Humira) on patient\u2010reported outcomes","volume":"102","author":"Loftus EV","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"S457[#922]","DOI":"10.14309\/00000434-200709002-00922","article-title":"Continuous vs induction only\/reinitiated adalimumab maintenance therapy yields optimal results for moderate to severe Crohn\u2019s disease: subanalysis of CHARM","volume":"102","author":"Colombel JF","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"e_1_2_6_32_2","first-page":"S1063","article-title":"Sustained improvement in quality of life for patients with fistulising crohn\u2019s disease treated with adalimumab: 3\u2003year data from CHARM","volume":"136","author":"Schwartz DA","year":"2009","journal-title":"Gastroenterology"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-2-199507150-00009"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200105000-00017"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6846.160"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02053756"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2009.04088.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2009.04088.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:13:57Z","timestamp":1697228037000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2009.04088.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,3]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1365-2036.2009.04088.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04088.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,3]]}}}